Value
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 2.7 |
| P/S | 10.0 |
| EV/EBITDA | 4.1 |
| Fwd P/E | 8.8 |
| PEG | 10.0 |
| Analyst target | 4.0 |
- ▸Forward P/E: 12.5x
- ▸PEG: 0.29
CVS · Why this verdict
Why CVS Health (CVS) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.5/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Overall quality sits at 3.3 out of 10 — below the 4.0 minimum threshold — driven by thin operating margins, weak return on assets, and the absence of a recognized competitive moat; this quality profile limits confidence in the durability of the current earnings beat streak. Bear case | Quality score rises above 4.0 for 2 consecutive quarterly evaluations, reflecting material improvement in margins or asset returns. | →Stable |
| CounterThin margins are structurally common across pharmacy benefits and retail pharmacy; the business may sustain adequate absolute returns through scale and free cash flow generation even without superior margin metrics. | ||
All four of the most recent quarterly results beat consensus, with an average positive surprise near 17%; this sustained delivery indicates management has set guidance that the business can reliably clear, even in a challenging healthcare cost environment. Earnings | At least three of the next four quarterly results beat consensus, maintaining the positive delivery record and confirming the beat cadence is structural. | →Stable |
| CounterEarnings beats in healthcare services can reverse quickly if medical cost ratios deteriorate — guidance that was once conservative may prove optimistic if utilization trends shift unexpectedly. | ||
Free cash flow runs at roughly 177% of reported net income — a strong conversion rate indicating the business generates substantially more cash than GAAP earnings reflect, providing a buffer for debt service, reinvestment, or capital return even when accounting earnings are under pressure. Quality breakdown | Free cash flow conversion stays above 120% of net income for four consecutive quarters, confirming the structural cash generation advantage is maintained. | →Stable |
| CounterA conversion ratio well above net income can reflect deferred capital spending or working-capital timing rather than structural superiority; if the business needs to accelerate investment, free cash flow could compress toward net income faster than the historical average suggests. | ||
An active legal risk event has triggered a gate failure, and the dividend yield carries a warning that it may be uncovered; both factors add tail risk that complicates the investment case, particularly given the stock is at its near-term price target with no reward remaining. Engine gate (failed) | The legal matter resolves without triggering a renewed gate failure, and dividend coverage improves to a level where free cash flow exceeds 100% of dividends paid for 2 consecutive quarters. | →Stable |
| CounterHealthcare legal proceedings are common and frequently resolved without material financial impact; until a specific liability is quantified, the legal gate failure may overstate the actual risk to the investment thesis. | ||
Overall quality sits at 3.3 out of 10 — below the 4.0 minimum threshold — driven by thin operating margins, weak return on assets, and the absence of a recognized competitive moat; this quality profile limits confidence in the durability of the current earnings beat streak.
→StableBear case
- Expectation
- Quality score rises above 4.0 for 2 consecutive quarterly evaluations, reflecting material improvement in margins or asset returns.
CounterThin margins are structurally common across pharmacy benefits and retail pharmacy; the business may sustain adequate absolute returns through scale and free cash flow generation even without superior margin metrics.
All four of the most recent quarterly results beat consensus, with an average positive surprise near 17%; this sustained delivery indicates management has set guidance that the business can reliably clear, even in a challenging healthcare cost environment.
→StableEarnings
- Expectation
- At least three of the next four quarterly results beat consensus, maintaining the positive delivery record and confirming the beat cadence is structural.
CounterEarnings beats in healthcare services can reverse quickly if medical cost ratios deteriorate — guidance that was once conservative may prove optimistic if utilization trends shift unexpectedly.
Free cash flow runs at roughly 177% of reported net income — a strong conversion rate indicating the business generates substantially more cash than GAAP earnings reflect, providing a buffer for debt service, reinvestment, or capital return even when accounting earnings are under pressure.
→StableQuality breakdown
- Expectation
- Free cash flow conversion stays above 120% of net income for four consecutive quarters, confirming the structural cash generation advantage is maintained.
CounterA conversion ratio well above net income can reflect deferred capital spending or working-capital timing rather than structural superiority; if the business needs to accelerate investment, free cash flow could compress toward net income faster than the historical average suggests.
An active legal risk event has triggered a gate failure, and the dividend yield carries a warning that it may be uncovered; both factors add tail risk that complicates the investment case, particularly given the stock is at its near-term price target with no reward remaining.
→StableEngine gate (failed)
- Expectation
- The legal matter resolves without triggering a renewed gate failure, and dividend coverage improves to a level where free cash flow exceeds 100% of dividends paid for 2 consecutive quarters.
CounterHealthcare legal proceedings are common and frequently resolved without material financial impact; until a specific liability is quantified, the legal gate failure may overstate the actual risk to the investment thesis.
TrendMatrix Research · core thesis
Engine thesis — one sentence
CVS Health has delivered four consecutive earnings beats with an average positive surprise near 17% and converts net income to free cash flow at a ratio of roughly 1.8 times. However, the stock has reached its near-term price target with zero headroom remaining and a reward-to-risk ratio at essentially zero, overall quality sits below the minimum threshold at 3.3 out of 10, and an active legal risk event has triggered a gate failure alongside a dividend safety warning.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 1.3 |
| ROA | 1.8 |
| Gross margin | 0.0 |
| Op margin | 1.6 |
| Net margin | 0.4 |
| Current ratio | 3.5 |
| FCF quality | 10.0 |
| Moat | 4.2 |
| Piotroski F | 6.7 |
- ▸Excellent cash conversion: 177% FCF/NI
- ▸No competitive moat
Growth
7.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 4.0 |
| EPS growth | 10.0 |
Momentum
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 3.9 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 0.9 |
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
7.7/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 8.5 |
| Analyst rating | 9.0 |
| Price target | 5.1 |
- ▸LLM news sentiment: +0.70 (n=4)
Insider
3.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Notable insider selling — $358,973,073 (0.269% of mkt cap)
Peer rank
4.6/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 4.4 |
| quality rank | 3.6 |
| growth rank | 5.5 |
Technical
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.8 |
| support resistance | 1.1 |
| 52w position | 9.7 |
Risk (lower is worse)
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 9.1 |
| days to cover | 7.9 |
| volatility | 6.8 |
| put call | 9.5 |
| implied vol | 6.6 |
| beta | 9.4 |
| debt equity | 5.0 |
Catalyst
6.9/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| dividend safety | 3.5 |
| news activity | 8.0 |
- ▸Perfect beat streak: 4Q
- ▸Yield trap warning: high yield but unsafe
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (5)
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:27d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:4.0<4.5
- ASYMMETRY:-0.8=NEGATIVE
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-0.82
Upside
-9.2%
Downside
11.2%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeCatalyst-Driven — Earnings in 27d with 4/4 beat streak
SuitabilityModerate — Balanced profile
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Risk (lower is worse) at 7.8 could not lift the engine output above the verdict floor. Failed gate signal: MOMENTUM:4.0<4.5.
The strongest dimensions are Risk (lower is worse) at 7.8, Sentiment at 7.7, and Growth at 7.0; the weakest are Insider at 3.3, Quality at 3.3, and Momentum at 4.0. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of -0.82 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Consistent Earnings Outperformance
Trip ifEPS surprise falls below 0% for 2 consecutive quarters.
- P2Strong Free Cash Flow Conversion
Trip ifFree cash flow conversion falls below 100% of net income for 2 consecutive quarters.
- P3Quality Below Minimum Floor
Trip ifQuality score rises above 4.0 for 2 consecutive quarterly evaluations.
- P4Legal Risk Dividend Safety
Trip ifFree cash flow exceeds 100% of dividends paid for 2 consecutive quarters AND legal news gate returns to passing status.